Skip to main content

Peer Review reports

From: Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma

Original Submission
21 Jun 2022 Submitted Original manuscript
5 Aug 2022 Reviewed Reviewer Report - Simone Morra
9 Aug 2022 Reviewed Reviewer Report - Ernesto Di Mauro
7 Oct 2022 Reviewed Reviewer Report - Naresh Kumar Saidha
14 Oct 2022 Author responded Author comments - Satoru Taguchi
Resubmission - Version 2
14 Oct 2022 Submitted Manuscript version 2
17 Oct 2022 Reviewed Reviewer Report - Simone Morra
17 Oct 2022 Reviewed Reviewer Report - Ernesto Di Mauro
27 Oct 2022 Reviewed Reviewer Report - Naresh Kumar Saidha
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
31 Oct 2022 Editorially accepted
9 Nov 2022 Article published 10.1186/s12894-022-01139-9

You can find further information about peer review here.

Back to article page